Dr Petra Dieterich
Dr Dieterich has 30 years’ experience of drug development in the pharmaceutical industry with a focus on supporting CMC activities. She has held leadership positions in Project Management, Technical Operations and Business Development. Working in the CRO and CDMO environment she has led projects for customers across the globe, helping them to achieve their goals in clinical trials and low volume commercial manufacture. Petra holds a D.Phil in synthetic organic chemistry and an MBA from Imperial College London.
ArticleWhy most T-cell engagers fail - and how to fix it
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
ArticleAntibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further ...